For the quarter ended June 2025, Teva Pharmaceutical Industries Ltd. (TEVA) reported revenue of $4.18 billion, up 0.3% over the same period last year. EPS came in at $0.66, compared to $0.61 in the year-ago quarter.
The reported revenue represents a surprise of -2.47% over the Zacks Consensus Estimate of $4.28 billion. With the consensus EPS estimate being $0.63, the EPS surprise was +4.76%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Teva Pharmaceutical Industries performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Geographic Revenue- Europe: $1.3 billion versus the five-analyst average estimate of $1.25 billion. The reported number represents a year-over-year change of +7%.
- Geographic Revenue- International Markets: $495 million compared to the $602.4 million average estimate based on five analysts. The reported number represents a change of -16.5% year over year.
- Geographic Revenue- United States: $2.15 billion versus $2.19 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +1.9% change.
- Geographic Revenue- United States- Anda: $365 million versus the four-analyst average estimate of $358.28 million. The reported number represents a year-over-year change of -2.1%.
- Geographic Revenue- Europe- COPAXONE: $50 million versus the four-analyst average estimate of $40.5 million. The reported number represents a year-over-year change of -5.7%.
- Geographic Revenue- Europe- Respiratory products: $55 million versus $55.07 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -3.5% change.
- Geographic Revenue- International Markets- Generic products: $410 million versus the four-analyst average estimate of $478.57 million. The reported number represents a year-over-year change of -15.6%.
- Geographic Revenue- International Markets- COPAXONE: $7 million versus $10.83 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -50% change.
- Geographic Revenue- United States- AJOVY: $63 million compared to the $50.8 million average estimate based on four analysts. The reported number represents a change of +50% year over year.
- Revenue- COPAXONE- Total: $119 million versus $101.85 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -19.6% change.
- Revenue- Other- Total: $232 million versus $259.03 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +118.9% change.
- Revenue- API sales to third parties: $135 million versus $156.49 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -10.6% change.
View all Key Company Metrics for Teva Pharmaceutical Industries here>>>
Shares of Teva Pharmaceutical Industries have returned -0.6% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
